Context: Severe short stature can be caused by defects in numerous biological processes including defects in IGF-1 signaling, centromere function, cell cycle control, and DNA damage repair. Many syndromic causes of short stature are associated with medical comorbidities including hypogonadism and microcephaly.
etal conditions that lead to significant proportionate short stature. At the extreme end of the spectrum lies microcephalic primordial dwarfism (MPD), a heterogeneous group of monogenic growth disorders consisting of severe intrauterine and postnatal growth restriction, leading to extreme short stature and disproportionate microcephaly (1) . Prominent examples of MPD include Seckel syndrome, microcephalic osteodysplastic primordial dwarfism (MOPD) types 1 and 2, and Meier-Gorlin syndrome. In addition to classic MPD, milder syndromic growth disorders include 3M syndrome, Russell-Silver syndrome, Cockayne syndrome, Bloom syndrome, and others. Many of these disorders do not have microcephaly as a prominent component and may not have as severe prenatal growth restriction, although the phenotypes are highly variable. Each syndrome may include specific dysmorphic features and the occurrence of comorbid conditions such as primary gonadal failure, insulin resistance, or developmental delay. Within the last decade, multiple genetic etiologies have been identified for these disorders, including defects in many fundamental biological processes such as IGF-1 signaling, cell cycle regulation, DNA replication, centrosome function, maintenance of microtubule and genome integrity, and DNA damage repair (1-13) among others.
In this study we present two siblings with a novel syndrome consisting of severe short stature, microcephaly, hypergonadotropic hypogonadism, and early-onset metabolic syndrome, as well as possible tumor susceptibility caused by an underlying XRCC4 mutation, a gene involved in the nonhomologous end-joining (NHEJ) DNA damage repair process.
Case Descriptions

Patient 1
Patient 1 (P1) is a male born at term small for gestational age, with a birth length of 45.0 cm (Ϫ2.8 SD score [SDS] ) but a normal birth weight of 2.92 kg (Ϫ1.3 SDS). He showed progressive growth failure throughout childhood ( Figure 1A ). His body mass index (BMI) was always within normal limits for age. He had bilateral cryptorchidism, with right orchiopexy at age 7 years and atrophy of the left testicle with a volume less than 1 cc. Hemithyroidectomy for multinodular goiter was performed at age 10. He subsequently had a mildly elevated TSH with normal T 4 and was started on lowdose levothyroxine supplementation.
He presented at age 13 with absent pubertal signs, micropenis with a stretched penile length of 3.5 cm, and a baseline T level of 10 ng/dL (Table 1) . He failed to enter puberty spontaneously but did not return for pubertal evaluation until the age of 18. At that time, laboratory analysis was consistent with primary gonadal failure with marked hypergonadotropic hypogonadism. Bone age was delayed by 4 years, and he was started on im T replacement therapy. He was variably compliant with T therapy and thus had poor virilization and did not reach final adult height until his mid-20s.
At the age of 16, he underwent an oral glucose tolerance test (OGTT) with a normal fasting blood glucose of 81 mg/dL and 2-hour blood glucose of 120 mg/dL. However, his insulin levels were significantly elevated (fasting, 33.7 IU/mL; 2-h, 219 IU/mL). At age 27, he was diagnosed with diabetes with negative anti-islet cell antibodies. He began metformin and insulin therapy in subsequent years, but due to poor compliance his hemoglobin A1c levels were consistently elevated. He was diagnosed with dyslipidemia, which was treated with a statin. At age 37, he underwent cataract surgery.
His most recent physical examination at age 39.9 years shows severe short stature (127.4 cm, Ϫ6.8 SDS), microcephaly with an occipital frontal circumference (OFC) of 51.3 cm (Ϫ3.3 SDS), a BMI of 20.3 kg/m 2 (Ϫ1.0 SDS), acanthosis, clinodactyly, small testes (Ͻ2 mL), and a highpitched voice ( Figure 1C ). He has always had low-normal hemoglobin levels and never showed clinical signs of immune deficiency. He had mild lymphopenia, and lymphocyte subpopulation analysis revealed a reduced number of natural killer (NK) and B cells with a mild decrease in CD4ϩ T cells, however, with normal numbers of CD8ϩ T cells. Complement analysis showed that C3 was mildly elevated, with a normal C4 level. His IgG, IgA, and IgM levels were all normal, but the IgE was elevated (Table 1) .
Patient 2
Patient 2 (P2), a sister of P1, was born with a short birth length of 46 cm (Ϫ2.3 SDS) and a birth weight of 2600 g (Ϫ1.9 SD). She was first brought to medical attention at the age of 2 years for progressive growth failure, similar to her older brother ( Figure 1B) . She failed to enter puberty spontaneously and was diagnosed with severe gonadal failure (hypergonadotropic hypogonadism) at age 16 (Table 1). She was started on estrogen replacement therapy, but due to poor compliance, she displayed persistent hypogonadism at age 19 with Tanner 1 breast development, Tanner 2 pubic hair, and absent axillary hair.
An OGTT performed at age 16 showed normal glucose tolerance with a fasting glucose of 81 mg/dL and a 2-hour glucose of 137 mg/dL. Similar to her brother, she demonstrated marked insulin resistance (fasting insulin, 28 IU/mL; 2-h insulin level, 180 IU/mL). At age 19, she was noted to have acanthosis on examination. As an adult, she had multiple elevated fasting blood sugars (peak, 154 mg/dL), but she never received medical therapy for diabetes. She also had significant dyslipidemia, which was untreated.
Unlike her brother, she did not have a history of cataract and/or thyroid surgery. She had a persistent anemia of unknown origin throughout childhood and young adulthood but no other signs of hematological or immunological disease. There was no history of frequent infections. She had normal Ig levels, with a mild elevation in C3 but normal C4. She did not have lymphocyte subsets performed.
At age 30, she was evaluated for left abdominal pain, which demonstrated a jejunal wall tumor 5 cm in diameter that was surgically removed. Pathological analysis was consistent with a gastrointestinal stromal tumor (GIST), and no adjuvant treatment was given at the time because of its benign prognosis. She did not have a history of acute radiation exposure or an increased cumulative radiation dose through repeated medical imaging before this diagnosis. At age 31, she returned to the oncology clinic and was found to have diffuse intra-abdominal metastases. Multiple thyroid nodules were also reported on ultrasound, but no tissue was obtained for analysis. She was started on imatinib therapy but was subsequently switched to sunitinib due to worsening of anemia and gastrointestinal side effects. Despite the tyrosine-kinase inhibitor treatment, the tumor continued to progress, resulting in her demise at age 36. Before her demise, her adult physical examination was remarkable for severe short stature (height, 137.4 cm; Ϫ4.0 SDS), microcephaly (head circumference, 50.5 cm; Ϫ2.9 SDS), micrognathia, triangular facies, high-pitched voice, short neck, clinodactyly, and acanthosis nigricans ( Figure 1C ).
Family history
The family is from rural Chile. The parents conceived a total of six children. The first two siblings (both male) died from respiratory infections at the ages of 7 and 4 months, respectively. Per report of the parents, both of the deceased children had normal birth weights and lengths, and they did not appear dysmorphic. Apart from the index patients (fifth and sixth children), the adult height of all family members was within the normal range for Chilean standards: father, 168 cm; mother, 155 cm; brother, 180 cm; and sister (S1), 157 cm. The siblings are generally healthy. S1 recently developed type 2 diabetes at age 40 but does not have a history of dyslipidemia, thyroid abnormalities, malignancy, or hematological or immunolog- ical disease. She has always had regular menses and had three spontaneous pregnancies. Her three children all had normal birth weight and normal childhood growth patterns.
Methods
This study was approved by the Institutional Review Board of the University of Chile. Written informed consent was obtained from the two affected siblings as well as their unaffected sister. Growth charts were generated with GrowthXP software, version 2 (PC PAL).
Genetic analysis
Details of the genetic analysis are provided in the Supplemental Data. For genome-wide single nucleotide polymorphism (SNP) analysis of P1, the Illumina HumanHap300 BeadChip (Illumina, Inc) was used, containing 317 000 TagSNPs, with an average spacing of approximately 9 kb. A total of 750 ng DNA was processed according to the manufacturer's protocol. SNP copy number (log R ratio) and B-allele frequency were assessed using Beadstudio Data Analysis Software version 3.2 (Illumina, Inc). Runs of homozygosity (ROH) scores were calculated using the Copy Number Variation (CNV) partition plug-in (CNV partitioner 1.2.1). The evaluation of CNVs was performed as previously described (14) . Candidate gene sequencing was performed using Sanger sequencing for genes involved in the IGF-1 signaling pathway (IGF1R, PIK3R1, PIK3R3, BMP3, PRKG2) and for the known causes of 3M syndrome (CUL7, OBSL1, and CCDC8). Because IGF1R deficiency can also be caused due to a deletion of a large part or the complete coding region, and it is not known what type of mutation to expect in PIK3R1 and PIK3R3, multiplex ligation-dependent probe amplification was performed for these three genes using custom in-house kits to assess for deletions or duplications. Exome sequencing was performed on subjects P1, P2, and S1 at the Cincinnati Children's Hospital Medical Center.
Analysis of XRCC4 cDNA from peripheral blood mononuclear cells (PBMCs) and primary dermal fibroblasts cultures
PBMCs were isolated from blood samples of the unaffected sister (S1) and proband P1. Primary fibroblast cultures of P1, established from a skin biopsy, were maintained as previously described (15) . cDNA was amplified and sequenced for XRCC4 as described in the Supplemental Data (reference transcript NM_022406.2).
Microhomology-mediated end-joining (MMEJ) assay
MMEJ assay was employed to evaluate the efficiency of NHEJ using linearized pDVG94 plasmid, as previously described (16) . The principle of this assay is to measure the relative efficiency of joining a double-stranded break at a specific location without the loss of a repetitive sequence via the NHEJ pathway vs repair via MMEJ, which results in the loss of one of these repeats. If the repair occurs via MMEJ, a BstXI restriction site is created. BstXI can then be added, and the products can be PCRamplified and separated by gel electrophoresis. Transfection was carried out using X-tremeGENE HP DNA Transfection Reagent (Roche Diagnostics). Briefly, primary fibroblasts from the proband P1, as well as normal and ligase IV-deficient fibroblasts, were transfected with linearized pDVG94. Extrachromosomal DNA was isolated 48 hours later, and junctions were PCR amplified, followed by restriction enzyme digestion with BstXI. PCR-amplified products were separated by gel electrophoresis and visualized using ethidium bromide.
Results
Genetic analysis
Candidate gene sequencing was performed for a number of genes in the IGF-1 signaling pathway as well as for the known genetic causes of 3M syndrome and produced normal results. These genes were selected since defects in the IGF-1 signaling pathway can lead to microcephalic dwarfism and 3M syndrome causes dwarfism with gonadal failure. A SNP array performed on subject P1 did not reveal any potentially pathogenic CNVs. Homozygosity analysis identified five large ROH located on separate chromosomes, ranging in size from 6.8 to 34 Mb (Supplemental Data). In total, there were 106 Mb of ROH consistent with a coefficient of inbreeding of 1/32 (17) , suggesting that the subject's parents were fourth-degree relatives (18) .
We next proceeded to perform exome sequencing on subjects P1 and P2 as well as the unaffected sister, S1. Given the SNP array findings, we hypothesized that the causal variant would be a rare variant found in the homozygous state in P1 and P2 and either heterozygous or absent in S1, and that this variant would fall into one of the areas of ROH found in P1. Because the subject's clinical presentation was quite severe, we excluded all variants present in the 1000 Genomes database (www.1000genomes.org) or our internal exome database (ϳ750 individuals) with a minor allele frequency greater than 0.005. There was only a single rare nonsynonymous variant that was homozygous in both P1 and P2 and either heterozygous or absent in S1. As expected, this variant was present in a region of homozygosity found in P1's SNP array. This was a novel variant in exon 3 of XRCC4, c.246TϾG, which was heterozygous in S1. This variant was confirmed to be homozygous in both P1 and P2 and heterozygous in S1 via Sanger sequencing (Figure 2A) . XRCC4 is an excellent candidate gene because DNA damage repair genes are known to be causal of a number of types of MPD.
cDNA evaluation
The exonic c.246TϾG variant is predicted to result in a p.Asp82Glu substitution. Aspartic acid at position 82, however, is not highly evolutionarily conserved, and the p.Asp82Glu missense variant is predicted to be benign by Polyphen2 (http://genetics.bwh.harvard.edu/pph2/) with a score of doi: 10.1210/jc.2015-1098 jcem.endojournals.org E793 0.317 (out of a maximum of 1.0). However, we noted that the TϾG transversion could create a new donor splice site with an in silico donor site score of 0.52, which was lower than the in silico donor site score of 0.95 for the normal exon 3 donor splice site ( Figure  2B ; http://www.fruitfly.org/seq_tools/ splice.html). To assess whether the TϾG transversion in fact could alter splicing events, we evaluated the XRCC4 cDNA in PBMC isolated from P1 and S1, compared to normal PBMC. The XRCC4 cDNA was PCR amplified as two fragments, with fragment 1 encompassing the protein peptide encoded by exons 2-7 ( Figure 2C ). In normal PBMCs, fragment 1 generated the expected approximately 980-bp PCR product ( Figure 2C ). P1 PBMC, in contrast, lacked the approximately 980-bp PCR product, with the largest PCR product approximately 900 bp, whereas S1 carried both the approximately 980-bp and approximately 900-bp products ( Figure 2C ). Fragment 2 from all three PBMC samples was of the same size (ϳ440-bp product) as expected. Sanger sequencing of fragment 1 revealed that P1 carried the homozygous c.246TϾG variant and deletion of the adjacent 69 base pairs, c.247_ 315del, which corresponded precisely to a splicing event from the novel 5Ј donor site ( Figure 2D ). The aberrant splicing would result in a predicted p.Asp82Glu substitution and an inframe loss of 23 amino acids (p.Val83_ Ser105del). The presence of homozygous XRCC4 cDNA c.246TϾG and c.247_315del was also observed in primary fibroblasts derived from P1. S1, as expected, was heterozygous for both c.246TϾG and c.247_315del ( Figure 2D ).
DNA damage repair functional analysis
We next investigated whether the XRCC4 mutation conferred a NHEJ defect, employing a MMEJ assay (19) in which linearized pDVG94 
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plasmid DNA was transfected into P1, normal control, and ligase IV-deficient fibroblasts. The 6-bp direct repeat at the junction of the linearized DNA ( Figure 3 ) can be joined either via a functional NHEJ ("direct") pathway or via a microhomology (MMEJ) mechanism, the latter distinguishable by sensitivity to the restriction enzyme BstXI (19) . As shown in Figure 3 , normal fibroblasts predominantly used the NHEJ pathway (resistant to BstXI digest), whereas the ligase IV-deficient fibroblasts that have severely impaired NHEJ switched almost exclusively to utilizing MMEJ (highly BstXI sensitive). Fibroblasts from P1 show a BstXI digest pattern strikingly similar to that of the ligase IV-deficient fibroblasts, providing functional evidence that the XRCC4 mutation also severely impaired NHEJ and, therefore, was the most probable cause of the observed phenotype in our patients.
Discussion
In this study we have identified a homozygous single nucleotide variant in the XRCC4 gene, c.246TϾG, as the probable cause of a novel primordial dwarfism syndrome consisting of severe short stature, microcephaly, primary gonadal failure, early-onset metabolic syndrome, and a possible tumor predisposition. We demonstrate that this variant not only resulted in an Asp82Glu exchange but also, importantly, induced a novel, aberrant splicing event that led to the predicted in-frame deletion of 23 amino acids (p.Val83_Ser105del). The biological consequence appears to be a severe impairment in NHEJ-mediated repair of double-stranded DNA breaks (DSBs). DSBs can be programmed, as for the physiological V(D)J (variable, diverse, joining) recombination process during lymphocyte maturation (20, 21) , but more often occur spontaneously or result from exogenous damaging agents such as ionizing radiation or alkylating agents, leading to genomic rearrangements if misrepaired or to cell death when unrepaired (22) . Cells use two mechanisms to repair this type of DNA damage: homologous recombination, in which a template of similar DNA sequence is used during the repair; or NHEJ, in which broken DNA ends are directly ligated to each other (21) . Efficient NHEJ repair, as might be expected, is a tightly regulated process requiring multiple proteins, including the DNA-dependent protein kinase catalytic subunits, the Ku70/80 heterodimer, Artemis, DNA ligase IV, XRCC4, and NHEJ1 (23) . Of these, XRCC4, together with NHEJ1 (alias XLF, XRCC4-like factor) and DNA ligase IV, is involved in the final stages of joining DSBs (20) . Based on the three-dimensional crystal structure of known XRCC4-NHEJ1 and XRCC4-DNA ligase IV interactions (24), we hypothesize that loss of the Val83 to Ser105 residues in our mutant XRCC4 specifically disrupted XRCC4-NHEJ1 interactions (XRCC4 contact points include Lys99 and Lys102) and lead to the loss of one of two DNA binding sites formed by the XRCC4-NHEJ1 interactions. This hypothesized loss of function is consistent with the functional studies utilizing primary fibroblasts from P1.
In a murine model, biallelic deficiency in XRCC4 results in a lethal embryonic phenotype with significant neuronal damage and extensive apoptosis, arrested lymphocyte development, as well as severe growth retardation and reduced fibroblast proliferation rates in vitro (25) . Simultaneous knockout of one or both alleles of the p53 tumor suppressor gene in XRCC4-deficient mice rescued the lethal embryonic neuronal phenotype, but these mice do develop pro-B-cell lymphomas at an early postnatal age, and the mice still displayed severe growth retardation, suggesting that XRCC4 deficiency leads to growth failure by a mechanism independent of the neuronal apoptosis (26) . Additionally, these mice demonstrate testicular atrophy, thus mimicking the phenotype seen in our patients (27) .
To date, there has not been a definitive link between pathogenic XRCC4 mutations and human disease. How- ever, in a recent study of genetic causes of primordial dwarfism, Shaheen et al (28) identified a homozygous missense variant in XRCC4 in a single 4-year-old female with MPD. Functional evidence for the pathogenicity of this missense variant was not provided. This patient exhibited marked short stature (Ϫ7.1 SDS) and profound microcephaly. Because the described child is still young, further phenotypic characterization in terms of pubertal growth and development, metabolic abnormalities, and propensity for tumor formation is not known at this time.
Deficiency in a number of the other components of the NHEJ complex including ligase IV, NHEJ1, Artemis, and DNA-dependent protein kinase catalytic subunits has been reported, all leading to a class of disorders entitled radiosensitive, severe combined immunodeficiency (29) . Patients with these disorders present with a wide spectrum of immunodeficiency ranging from mild B-cell deficiency with no clinical symptoms to severe neonatal combined immunodeficiency. Many of these patients have short stature and microcephaly as well as a predisposition to lymphoma (29) . In a recent paper by Murray et al (30) , 11 MPD patients were described with biallelic truncating LIG4 mutations. This well-phenotyped group of ligase IV-deficiency patients displays a phenotypically diverse spectrum consisting of proportionate intrauterine growth restriction (mean: birth length, Ϫ3.8 SDS; birth weight, Ϫ3.0 SDS; OFC, Ϫ3.6 SDS), severe postnatal growth failure (mean: height, Ϫ5.1 SDS; weight, Ϫ6.8 SDS), with disproportionate microcephaly (mean: OFC, Ϫ10.1 SDS), mild to moderate developmental delay, premature ovarian failure in the peripubertal patients, distinct skin and skeletal abnormalities, as well as facial dysmorphisms (30) . Although immunodeficiency was not clinically suspected in 10 of 11 studied patients, most of these patients had hypogammaglobulinemia and decreased B-cell counts, whereas T-cell function appeared to be less affected. In addition to the immunodeficiencies, progressive bone marrow dysfunction was observed in most patients, most notably early-onset thrombocytopenia, but also leukopenia and mild anemia.
In comparison, our two patients with XRCC4 mutations did not show any signs of clinically significant immune deficiency throughout life. However, upon detailed immunophenotyping, P1 was found to have a number of distinct immunological abnormalities, including mild lymphopenia, an elevated C3 level, and a reduction in B and NK cells. Because NK cells are not part of the adaptive immune system and therefore not directly involved in the process of V(D)J rearrangements, the underlying mechanism is not clear at this time. However, similar NK cell deficiencies have been described in patients with primordial dwarfism due to a mutation in the MCM4 gene, which is involved in DNA replication and genomic stability (3). Except for a mildly elevated IgE level, P1 had normal Ig levels and normal T-cell subsets. P2 did show a mild, chronic anemia throughout life, which appeared to be due to bone marrow dysfunction after other potential causes such as iron or vitamin deficiencies and hemoglobinopathies had been excluded. Neither of our two patients had documented thrombocytopenia or leukopenia. However, given the wide spectrum of immunodeficiency seen in patients with defects in NHEJ, future immunological studies in patients with XRCC4 mutations are clearly warranted.
Similar to the two peripubertal ligase IV deficiency patients (30), both of our patients exhibited marked primary gonadal failure (hypergonadotropic hypogonadism) from childhood onward. Both needed complete hormonal replacement therapy for pubertal induction and maintenance of adult secondary sex characteristics. Gonadal failure is seen in other DNA repair syndromes, including the recently described MCM9 mutation affecting homologous recombination (31) . Other well-known primordial dwarfism syndromes are also known to have hypergonadotropic hypogonadism, including the 3M syndrome (32) . As stated previously, the murine model of XRCC4-deficient mice also display primary gonadal failure with marked testicular atrophy (27) . The above findings clearly indicate the sensitivity of gonadal tissues to the effects of DSBs and the deleterious effects of abnormalities in DNA repair.
A well-known feature of many of the DNA repair syndromes is a marked predisposition for tumor formation, often from an early age onward. Functional defects in NHEJ predispose to genomic rearrangements and chromosomal translocations, which can lead to tumorigenesis (33) . P2 developed a rare GIST at the age of 28 years. Because the large majority of GIST tumors (90%) occur in persons over age 40, with a median age of presentation reported between 59 and 63 years, a tumor predisposition phenotype is clearly suggested in her case (34, 35) . It has been well described that prior exposure to ionizing radiation in DNA repair syndromes greatly enhances tumor risk and often generates the crucial hit in tumorigenesis. Although P2 had no clear history of ionizing radiation exposure, the significant impairment in DNA damage repair seen in P1's fibroblasts, as well as his family history, strongly suggest that repeated x-ray or computed tomography imaging should be avoided. Most GIST tumors are sensitive to tyrosine kinase inhibitor therapy, but P2 had tumor progression under both imatinib and second-line sunitinib therapy. This may suggest that the tumorigenesis of her GIST could be influenced by the presence of XRCC4 deficiency. Detailed studies of the mutational spectrum in her tumor may provide insights into the lack of treatment response.
The early onset of insulin resistance, type 2 diabetes, and dyslipidemia in both of our patients, in the context of a negative family history, strongly suggests that these metabolic abnormalities are part of the phenotypic spectrum of XRCC4 deficiency. Some of the other dwarfism syndromes, most notably MOPD-2, display a similar clinical picture. Most patients with MOPD-2 develop significant insulin resistance during childhood, leading to acanthosis nigricans and type 2 diabetes mellitus (36) . The mechanism behind the marked insulin resistance remains unknown at present. However, in a study by Tavan et al (37) , it was shown that mice with a defect in NHEJ and a hypomorphic p53 mutation showed a progressive decrease in pancreatic islet mass independent of apoptosis and innate immunity. The authors concluded that combined DSBs with an absence of p53-dependent apoptosis lead to p53-dependent senescence, diminished ␤-cell self-replication, depletion of pancreatic islets, and a severe diabetic phenotype. Our patients appear to have insulin resistance as the primary mediator of their diabetes, but it is possible that a similar mechanism is contributing in their cases as well.
Our patients both displayed severe postnatal growth failure, leading to marked short stature of Ϫ7 and Ϫ4 SDS. There was only minor intrauterine growth restriction, which is different from patients with other underlying causes of primordial dwarfism, including the functionally related ligase IV deficiency. Also, the degree of microcephaly in our patients is less than encountered in the patients with ligase IV deficiency. It is unknown whether this will be a uniform feature of all patients with XRCC4 deficiency or whether our patients have a milder variant.
In conclusion, our study shows that mutations in XRCC4 add to the wide phenotypic spectrum of DNA repair enzyme syndromes. Although we cannot be certain that this single variant in XRCC4 accounts for all aspects of our patients' phenotype, it is a clear candidate variant to explain the short stature and gonadal failure and possibly the cancer susceptibility. XRCC4 mutations may be responsible for a number of patients with unidentified causes of severe short stature and associated primary gonadal failure.
